Celgene Wins Chinese Approval for Revlimid

Before you go, we thought you'd like these...
Before you go close icon

Biotech company Celgene has announced that its subsidiary Celgene International Sàrl has won full regulatory approval from the China State Food and Drug Administration for Revlimid.

Revlimid, used to treat relapsed or refractory multiple myeloma in patients who have already undergone at least one therapy, is expected to be available to Chinese patients sometime late in the second quarter. The drug, which is already approved in numerous other locations, recorded more than $3.7 billion in sales in 2012.

Additionally, Celgene said in the press release that the U.S. Food and Drug Administration has assigned a priority review to the company's filing to use Revlimid to treat patients with relapsed or refractory mantle cell lymphoma. The FDA's decision date of that filing has been set for June 5.


link

The article Celgene Wins Chinese Approval for Revlimid originally appeared on Fool.com.

Fool contributor Dan Carroll has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Read Full Story

Want more news like this?

Sign up for Finance Report by AOL and get everything from business news to personal finance tips delivered directly to your inbox daily!

Subscribe to our other newsletters

Emails may offer personalized content or ads. Learn more. You may unsubscribe any time.

From Our Partners